'The drug, donanemab, to be sold under the brand name Kisunla, was shown in studies to modestly slow the pace of cognitive decline in early stages of the disease. It also had significant safety risks, including swelling and bleeding in the brain.'

https://www.nytimes.com/2024/07/02/health/alzheimers-treatment-kisunla-donanemab.html